I agree that this site is using cookies. You can find further informations here.
X
Blagden, Sarah P.
127  results:
Search for persons X
?
1

A phase I open-label, dose-escalation study of NUC-3373, a ..:

Spiliopoulou, Pavlina ; Kazmi, Farasat ; Aroldi, Francesca...
Journal of Experimental & Clinical Cancer Research.  43 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
2

A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhib..:

Janku, Filip ; Choong, Grace M. ; Opyrchal, Mateusz...
Cancers.  16 (2024)  6 - p. 1137 , 2024
Link: https://doi.org/10.3390/..
 
?
3

Cancer Precision-Prevention trial of Metformin in adults wi..:

Dixon-Zegeye, Miriam ; Shaw, Rachel ; Collins, Linda...
Trials.  25 (2024)  1 - p. , 2024
Link: https://doi.org/10.1186/..
 
?
4

Phase I/II sequencing study of azacitidine, epacadostat, an..:

Luke, Jason J. ; Fakih, Marwan ; Schneider, Charles...
British Journal of Cancer.  128 (2023)  12 - p. 2227-2235 , 2023
Link: https://doi.org/10.1038/..
 
?
5

Additional consensus recommendations for conducting complex..:

Blagden, Sarah P. ; Yu, Ly-Mee ; Ellis, Stephanie...
British Journal of Cancer.  128 (2022)  3 - p. 474-477 , 2022
Link: https://doi.org/10.1038/..
 
?
6

Targeting MAPK in recurrent, low-grade serous ovarian cance:

Blagden, Sarah P
The Lancet.  399 (2022)  10324 - p. 499-501 , 2022
Link: https://doi.org/10.1016/..
 
?
7

First-in-human phase I/II, open-label study of the anti-OX4..:

Davis, Elizabeth J ; Martin-Liberal, Juan ; Kristeleit, Rebecca...
Journal for ImmunoTherapy of Cancer.  10 (2022)  10 - p. e004235 , 2022
Link: https://doi.org/10.1136/..
 
?
8

A source of hope for platinum-resistant ovarian cancer?:

Blagden, Sarah P ; Nicum, Shibani
The Lancet.  397 (2021)  10271 - p. 254-256 , 2021
Link: https://doi.org/10.1016/..
 
?
9

The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Ca..:

Schwenzer, Hagen ; De Zan, Erica ; Elshani, Mustafa...
Clinical Cancer Research.  27 (2021)  23 - p. 6500-6513 , 2021
Link: https://doi.org/10.1158/..
 
?
10

Adipocyte-like signature in ovarian cancer minimal residual..:

Artibani, Mara ; Masuda, Kenta ; Hu, Zhiyuan...
JCI Insight.  , 2021
Link: https://doi.org/10.1172/..
 
?
11

A decade of LARP society:

Blagden, Sarah P. ; Bayfield, Mark ; Bousquet-Antonelli, Cecile
RNA Biology.  18 (2021)  2 - p. 157-158 , 2021
Link: https://doi.org/10.1080/..
 
?
12

LARP1 isoform expression in human cancer cell lines:

Schwenzer, Hagen ; Abdel Mouti, Mai ; Neubert, Pia...
RNA Biology.  18 (2020)  2 - p. 237-247 , 2020
Link: https://doi.org/10.1080/..
 
?
13

Effective delivery of Complex Innovative Design (CID) cance..:

Blagden, Sarah P. ; Billingham, Lucinda ; Brown, Louise C....
British Journal of Cancer.  122 (2020)  4 - p. 473-482 , 2020
Link: https://doi.org/10.1038/..
 
?
14

NUC-1031, use of ProTide technology to circumvent gemcitabi..:

Kapacee, Zainul Abedin ; Knox, Jennifer J. ; Palmer, Daniel...
Medical Oncology.  37 (2020)  7 - p. , 2020
Link: https://doi.org/10.1007/..
 
?
15

Weekly platinum-based chemotherapy versus 3-weekly platinum..:

Blagden, Sarah P ; Cook, Adrian D ; Poole, Christopher...
The Lancet Oncology.  21 (2020)  7 - p. 969-977 , 2020
Link: https://doi.org/10.1016/..
 
1-15